Switzerland has officially become the 23rd nation in the world to approve Sativex for use by those with multiple sclerosis; Sativex is a medical spray made up entirely of cannabis-derived cannabinoids.
“This approval in Switzerland marks yet another regulatory success for Sativex, which is now approved in a total of 23 countries,” stated Justin Gover, Chief Executive Officer of GW Pharmaceuticals, the company behind the product. “We now look forward to working with our partners.. towards this launch so as to enable MS patients in Switzerland to benefit from this important new treatment.”
According to the company’s press release; “Sativex is approved for use in the treatment of MS spasticity in 23 countries, including 17 countries in Europe. The medicine is currently available on prescription in the UK, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland with launches currently in preparation for a further 8 European countries, as well as Australia, New Zealand and Kuwait.”